WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318851

CAS#: 58-46-8

Description: Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntington's disease (HD), the first in the US. The precise mechanism of action of tetrabenazine is unknown. The antichorea effect is believed to be related to its effect as a reversible depletory of monoamines (such as dopamine, serotonin, norepinephrine and histamine)from nerve terminals) Tetrabenazine reversibly inhibits VMAT-2 resulting in decreased of monamines into synaptic vesicles

Chemical Structure

CAS# 58-46-8

Theoretical Analysis

MedKoo Cat#: 318851
Name: Tetrabenazine
CAS#: 58-46-8
Chemical Formula: C19H27NO3
Exact Mass: 317.19909
Molecular Weight: 317.429
Elemental Analysis: C, 71.89; H, 8.57; N, 4.41; O, 15.12

Price and Availability

Size Price Availability Quantity
100.0mg USD 150.0 2 Weeks
200.0mg USD 250.0 2 Weeks
500.0mg USD 450.0 2 Weeks
1.0g USD 750.0 2 Weeks
2.0g USD 1450.0 2 Weeks
5.0g USD 3250.0 2 Weeks
Bulk inquiry

Synonym: Tetrabenazine; trade names Nitoman and Xenazin

IUPAC/Chemical Name: (3S,11bS)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one


InChi Code: InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m0/s1

SMILES Code: O=C1[C@@H](CC(C)C)CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 317.429 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: [Tetrabenazine (tetrabenazine Orphan) orally]. J Pharm Belg. 2014 Dec;(4):49-50. Review. French. PubMed PMID: 25562927.

2: Machida K, Kawakami D, Miki M. [Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement]. Nihon Yakurigaku Zasshi. 2014 Mar;143(3):144-51. Review. Japanese. PubMed PMID: 24614638.

3: Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012 Jul;34(7):1487-504. doi: 10.1016/j.clinthera.2012.06.010. Epub 2012 Jun 28. Review. PubMed PMID: 22749259.

4: Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149. Review. PubMed PMID: 22014129.

5: Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011 Apr;45(4):525-31. doi: 10.1345/aph.1P312. Epub 2011 Apr 12. Review. Erratum in: Ann Pharmacother. 2011 May;45(5):690. PubMed PMID: 21487088.

6: Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73. doi: 10.1016/j.amjopharm.2010.08.006. Review. PubMed PMID: 20869622.

7: Poon LH, Kang GA, Lee AJ. Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9. doi: 10.1345/aph.1M582. Epub 2010 May 4. Review. PubMed PMID: 20442355.

8: Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. doi: 10.1517/14656560903386292. Review. PubMed PMID: 19929707.

9: Setter SM, Neumiller JJ, Dobbins EK, Wood L, Clark J, DuVall CA, Santiago A. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Consult Pharm. 2009 Jul;24(7):524-37. Review. PubMed PMID: 19689181.

10: Tetrabenazine (Xenazine) for Huntington's chorea. Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8. Review. PubMed PMID: 19172140.

11: Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28(7):443-59. Review. PubMed PMID: 18544005.

12: Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan;6(1):7-17. Review. PubMed PMID: 16466307.

Additional Information

Other possible CAS#
CAS#718635-93-9 (Tetrabenazine)
CAS#804-53-5 (Tetrabenazine methanesulfonate)
CAS#2105-47-7 (Tetrabenazine hydrochloride)
CAS#1026016-83-0 (Tetrabenazine, (+)-)
CAS#1026016-84-1 (Tetrabenazine, (-)-)